|
| Status |
Public on Feb 18, 2015 |
| Title |
Control, biological rep.1 |
| Sample type |
RNA |
| |
|
| Source name |
MDA-MB-231 cells, control
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: MDA-MB-231
cell type: breast cancer cell line
treatment: DMSO control
treatment duration: 14 days
|
| Treatment protocol |
Exponentially growing MDA-MB-231 cells were plated, in duplicate, in 6-well plates at a density of 1 × 10^5 cells/ml in the presence of compounds for 14 days. Compounds and media were refreshed every 3-4 days. siRNA experiments were performed for 7 days by transfecting MDA-MB-231 cells with X-tremeGENE Transfection Reagent (Roche) and 10 nM siRNA (Invitrogen), according to the manufacturer's protocol.
|
| Growth protocol |
Human cell line MDA-MB-231 was obtained from the American Type Culture Collection (ATCC) and cultured using ATCC recommended culture media in a humidified incubator supplemented with 5% CO2 at 37°C.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Cells were lysed immediately in TRIzol® Reagent, frozen in liquid nitrogen, and shipped to Asuragen, Inc. (Austin, TX) for microarray experiments.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Illumina TotalPrep with QC for Illumina arrays.
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol.
|
| Scan protocol |
Standard Illumina scanning protocol.
|
| Description |
SAMPLE 1
Replicate 1 of 2.
|
| Data processing |
The background-subtracted data generated by BeadStudio Software were log2 transformed and then normalised by median centering.
|
| |
|
| Submission date |
Apr 08, 2014 |
| Last update date |
Feb 18, 2015 |
| Contact name |
Yongcheng Song |
| Organization name |
BAYLOR COLLEGE OF MEDICINE
|
| Department |
PHARMACOLOGY
|
| Street address |
One baylor plaza, Baylor College of Medicine
|
| City |
Houston |
| State/province |
TX |
| ZIP/Postal code |
77030 |
| Country |
USA |
| |
|
| Platform ID |
GPL10558 |
| Series (1) |
| GSE56630 |
Expression profiling of MDA-MB-231 breast cancer cells treated with DOT1L inhibitors and siDOT1L |
|
